EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseOpen Access

Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity

Bart Heeg iD, Andre Verhoek, Gabriel Tremblay, Ofir Harari, Mohsen Soltanifar, Haitao Chu iD, Satrajit Roychoudhury iD, Joseph C Cappelleri iD

Journal of Comparative Effectiveness Research · 2023-03 · 12 (3)

DOI: 10.2217/cer-2022-0159 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift Journal of Comparative Effectiveness Research, 2023-03. Verfasst von Bart Heeg und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cytel RWAA, Weena 316, 3012 NJ, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

This research evaluated standard Weibull mixture cure (WMC) network meta-analysis (NMA) with Bayesian hierarchical (BH) WMC NMA to inform long-term survival of therapies. Materials & methods: Four trials in previously treated metastatic non-small-cell lung cancer with PD-L1 >1% were used comparing docetaxel with nivolumab, pembrolizumab and atezolizumab. Cure parameters related to a certain treatment class were assumed to share a common distribution.

Results

Standard WMC NMA predicted cure rates were 0.03 (0.01; 0.07), 0.18 (0.12; 0.24), 0.07 (0.02; 0.15) and 0.03 (0.00; 0.09) for docetaxel, nivolumab, pembrolizumab and atezolizumab, respectively, with corresponding incremental life years (LY) of 3.11 (1.65; 4.66), 1.06 (0.41; 2.37) and 0.42 (-0.57; 1.68). The Bayesian hierarchical-WMC-NMA rates were 0.06 (0.03; 0.10), 0.17 (0.11; 0.23), 0.12 (0.05; 0.20) and 0.12 (0.03; 0.23), respectively, with incremental LY of 2.35 (1.04; 3.93), 1.67 (0.68; 2.96) and 1.36 (-0.05; 3.64).

Conclusion

BH-WMC-NMA impacts incremental mean LYs and cost–effectiveness ratios, potentially affecting reimbursement decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansDocetaxelNivolumabBayes Theorem

Stichwörter der Autor:innen

bayesian hierarchical modellingimmunotherapiesindirect treatment comparisonsmixture curenetwork meta-analysisoncologysurvival extrapolation

Substanzen

DocetaxelNivolumab

Autor:innen und Institutionen

  • Cytel RWAA, Weena 316, 3012 NJ, Rotterdam, The Netherlands.
  • Cytel RWAA, Canada.
  • Pfizer Inc, 445 Eastern Point Road, MS 8260-2502, Groton, CT 06340, USA.
  • Pfizer Inc., 235 E 42nd St, New York, NY 10017, USA.

ORCID-Profile: Bart Heeg, Haitao Chu, Satrajit Roychoudhury, Joseph C Cappelleri

Zitieren

APA

Heeg, B., Verhoek, A., Tremblay, G., Harari, O., Soltanifar, M., Chu, H., Roychoudhury, S., & Cappelleri, J. C. (2023). Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity. Journal of Comparative Effectiveness Research, 12(3). https://doi.org/10.2217/cer-2022-0159

Vancouver

Heeg B, Verhoek A, Tremblay G, Harari O, Soltanifar M, Chu H, et al. Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity. Journal of Comparative Effectiveness Research. 2023;12(3). doi:10.2217/cer-2022-0159

BibTeX
@article{Heeg2023,
  author = {Heeg, Bart and Verhoek, Andre and Tremblay, Gabriel and Harari, Ofir and Soltanifar, Mohsen and Chu, Haitao and Roychoudhury, Satrajit and Cappelleri, Joseph C},
  title = {Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2023},
  volume = {12},
  number = {3},
  doi = {10.2217/cer-2022-0159}
}
Kostenlos starten →